Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

(2021) Cassandra Aldrich et al.   VACCINE

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

(2021) Florian Krammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19: People who have had infection might only need one dose of mRNA vaccine

(2021) Jacqui Wise   BMJ-British Medical Journal

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

(2021) Johanna Chapin-Bardales et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

(2021) Susanne Rauch et al.   npj Vaccines

SARS-CoV-2 Variants and Vaccines

(2021) Philip R. Krause et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

The promise of mRNA vaccines: a biotech and industrial perspective

(2020) Nicholas A. C. Jackson et al.   npj Vaccines

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples

(2020) Alessandro Manenti et al.   JOURNAL OF MEDICAL VIROLOGY

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

(2020) Yuan Huang et al.   ACTA PHARMACOLOGICA SINICA

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

(2020) Jingyun Yang et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

(2020) Jérôme Hadjadj et al.   SCIENCE

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

(2020) Huibin Lv et al.   Cell Reports

Global impact of COVID-19 infection requiring admission to the intensive care unit: a systematic review and meta-analysis

(2020) Elinor Tan et al.   CHEST

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

(2020) Paul Bastard et al.   SCIENCE

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

(2018) Robert N. Kirchdoerfer et al.   Scientific Reports

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

(2017) Martin Alberer et al.   LANCET

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

(2017) Jesper Pallesen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

(2017) Johannes Lutz et al.   npj Vaccines